Navigation Links
Keraderm to Release $100 Phototherapy Treatment for Fungal Nail Infections
Date:9/17/2008

HAMPTON, Va., Sept. 17 /PRNewswire/ -- Keraderm, a leader in the development of phototherapy treatments for infections, plans to introduce a $100 phototherapy treatment for fungal nail infections (onychomycosis) in 2009 upon completion of their current pivotal trials and pending marketing clearance from the FDA.

"Our goal," states Keraderm CEO Bill Cumbie, "is to develop a safe and effective treatment for onychomycosis that can be accessed by a large number of people at a low cost. Many people cannot use current medications due to their high cost, significant side effects, and contraindications while taking other medications. Our pilot clinical trials have indicated the efficacy of the best oral medications with no significant side effects. We will establish the safety and efficacy of our treatment with our current pivotal clinical trials which will be submitted to the FDA for approval as the first phototherapy treatment for onychomycosis. The beauty of our treatment is that it can be delivered easily and inexpensively. We hope to introduce our treatment in 2009 at $100 for several treatments and continue to improve the technology so that eventually only one treatment in the $100 range will be necessary. We are also working to establish insurance reimbursement for our therapy which will further reduce cost to the consumer."

Keraderm is well on the way to being the first phototherapy treatment approved by the FDA for onychomycosis with its research published in the prestigious peer-reviewed British Journal of Dermatology and presented at the 2007 World Congress of Dermatology and the 2008 Annual Conference of the American Academy of Dermatology. Keraderm also has a growing portfolio of national and international patents that protect the key aspects of its proprietary platform technology to treat infections.

About Keraderm

Keraderm LLC is a medical device company with proprietary, patented, platform technology for a wide variety of infections. This technology has the potential to effectively treat infections without the serious side effects that many medications have and to effectively treat infections caused by drug resistant organisms such as MRSA. Keraderm has obtained patents on its key technologies to treat infections and has a number of additional patent applications pending on refinements of its technology. Published laboratory and clinical studies indicate that the technology has great potential to effectively and safely treat infections.

Forward-looking statements

Statements in this press release containing the words believe, may, expect, project and other similar expressions are forward looking statements that are not definite and have a number of risks and uncertainties. Representative factors that can cause actual results to differ from those projected include the following: regulatory clearance of products, market acceptance; financial constraints; government regulations; obtaining and enforcing intellectual property rights; attracting and retaining key employees; developing partnership opportunities; timing of commercial product launches; and other similar internal and external risks factors.

Media Contact:

Bill Cumbie

144 Research Drive

Hampton, VA 23666

(757) 344-8607

http://www.keraderm.com

bill@keraderm.com

This release was issued through eReleases(TM). For more information, visit http://www.ereleases.com.


'/>"/>
SOURCE Keraderm LLC
Copyright©2008 PR Newswire.
All rights reserved

Related medicine technology :

1. Sarasotas Roskamp Institute Releases Study Defining a Mechanism for Development of Obesity and the Metabolic Syndrome, Forerunners of Type 2 Diabetes
2. Tourtellotte Solutions Blazes Trail with New Release of Clinical Trial Supply Chain Simulator
3. CEL-SCI Corporation Releases Letter to Shareholders
4. Boston Scientific to Release Broad Range of Clinical Trial Data Reinforcing Safety and Efficacy of Taxus(R) Coronary Stent Systems at TCT 2007
5. AcroMetrix Releases New OptiQuant(R) HIV-1 Quantification Panel
6. ASCO and ASH Release Updated Guideline on the Use of Chemotherapy-Related Anemia Treatments in Cancer Patients
7. New Data Show Improvements in Work Performance in Patients with Chronic Insomnia Treated with AMBIEN CR(R) (zolpidem tartrate extended-release) Tablets CIV
8. Cardinal Health Releases New Tool to Combat MRSA Infections in Hospitals
9. Immunosyn Corporation Releases SF-1019 Study Results
10. UCB Announces Positive Phase III Trial Results for Keppra XR(TM) (levetiracetam) Extended-Release Tablets
11. Keppra XR(TM) Extended-Release Tablets Filed with the FDA
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:12/8/2016)... Australia Ophthalmic Lasers Market Outlook to 2022 Summary ... to 2022", provides key market data on the Australia ... of US dollars, volume (in units) and average prices ... and YAG Lasers. The report also provides company ... market segements, and global corporate-level profiles of the key ...
(Date:12/8/2016)... Dec. 8, 2016  The global biosurgery market is ... the forecast period of 2016 to 2021. The market ... from USD 18.21 billion in 2016. The market is ... of sports related injuries and spinal problems, increasing clearance ... of effective blood loss management. In this ...
(Date:12/8/2016)... Dec. 8, 2016 KEY FINDINGS ... share of the market in 2016 and is expected ... be attributed to a large number of surgical procedures ... the largest share in the patient temperature management market.) ... as reducing loss of blood during surgeries, lowering the ...
Breaking Medicine Technology:
(Date:12/9/2016)... ... December 09, 2016 , ... The American Speech-Language-Hearing Association ... a critical part of public access to hearing aid technology. , ASHA emphasized ... week that, starting immediately, it would no longer enforce the requirement that ...
(Date:12/9/2016)... ... December 09, 2016 , ... "I have gout, and I wanted to ... recipe, which is meant to relieve gout and pain caused by varicose veins. I ... boost every time. It relieved what VA doctors called the worst sinusitis case they'd ...
(Date:12/9/2016)... ... December 09, 2016 , ... Mediaplanet today announces distribution of the latest edition ... to sign up as an organ donor for the 123,000 people in the United ... donor can save up to 8 saves through organ donation and enhance many others ...
(Date:12/9/2016)... ... December 09, 2016 , ... The Pennsylvania Athletic ... (PCN) during the summer of 2016. The program was made possible by a ... States Department of Health and Human Services Administration. The broadcast, Use Your ...
(Date:12/8/2016)... ... December 08, 2016 , ... ... LLC, announced the first national #QuackGivesBack campaign which supported local breast cancer organizations ... first franchise-wide Quack Gives Back initiative, and we’re very pleased with ...
Breaking Medicine News(10 mins):